Drug intelligence / Profile preview

IMNN-201

Development stage: Preclinical
Lead developer: IMUNON
Modality: Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
Administration: Unknown

Overview

IMNN-201 is a preclinical DNA-based cancer vaccine being developed by Imunon. It is designed using the FixPlas platform to target the Trp2 (tyrosinase-related protein 2) tumor-associated antigen, with the goal of inducing an immune response against melanoma cells expressing this antigen. The vaccine aims to stimulate the body's immune system to recognize and attack melanoma tumors by presenting Trp2 antigens, potentially improving outcomes for patients with melanoma[1][5].

Targets

TYRP2 (Tyrosinase-related Protein 2)

Beyond the preview

Go deeper on IMNN-201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMNN-201.